Search the Psychiatry & Clinical Psychology desk archive.
A large trial found that sleep regularity was linked to depression outcomes, with consistency in sleep timing predicting symptom improvement more strongly than total sleep duration. The findings suggest that stabilizing sleep schedules could be a practical target for behavioral activation in depression care.
A newly reported study of adults in the United States and China suggests that older adults tend to be more generous toward people with whom they have weaker social connections. The age-related difference appeared in how people treated more distant ties rather than only those closest to them. This matters because it challenges assumptions that generosity necessarily narrows with age and suggests that charities, community groups and policymakers should consider how age shapes whom people are willing to help.
The article examines why dopamine D2 receptor blockade alone is insufficient in schizophrenia, pointing to the disorder’s broader biological complexity. It considers neurotransmitter, genetic and neuroimaging research and what those findings imply for patients who remain treatment-resistant.
New research is examining whether diets high in ultra-processed foods during childhood may affect the brain’s reward circuitry. The work links early eating patterns to dopamine-related reward processing and raises questions about food addiction and possible lasting effects. For professionals, it highlights a need to watch emerging evidence on how childhood nutrition may shape neural development and related health risks.
A new study reports that hope is linked to better outcomes in education, economic results, resilience, and people's ability to adapt to life's challenges. The findings frame hope as a factor with measurable consequences rather than a vague sentiment. For professionals, that suggests value in treating hope as something to assess and cultivate within education, workforce, and support programs.
Research suggests that appreciation, the practice of noticing and valuing what is already present, is linked to greater life satisfaction and a sense of psychological wealth. The takeaway is to start with ordinary, easily overlooked moments rather than waiting for major events. For professionals, it is a low-cost habit worth building into daily routines and, potentially, into how teams mark progress.
A commentary in this piece examines heterogeneity within major depression and argues for rethinking how multimodal models predict antidepressant response, rather than treating patients as a single homogeneous group. It frames the broader question of where AI can genuinely add value in modeling for diagnosis and clinical trials. For professionals working on precision psychiatry, the emphasis matters: prediction efforts that ignore subtype and symptom variability risk producing models that look promising in aggregate but fail in practice.
New artificial intelligence methods are being applied to small, noisy psychiatric trial datasets to identify clearer subgroups of depression and schizophrenia. The approach uses model abstention—declining to classify uncertain cases—to improve interpretability and support better patient stratification. For clinical trial professionals, this suggests a promising way to refine subgroup analysis, while underscoring the need to account for limited and noisy data before drawing firm conclusions.
Alkermes has begun a phase 2 study of ALKS 7290, an oral orexin-2 agonist, as adjunctive treatment for major depressive disorder. The trial will evaluate safety and symptom relief, with the aim of improving antidepressant response in patients who need additional benefit. For professionals, it tests a differentiated mechanism in the adjunctive MDD space, where better options remain needed for inadequate response.
Psychedelic trials are revealing a gap between efficacy seen in controlled settings and readiness for real-world care. Because studies often exclude patients with common comorbidities, clinicians must account for limits in blinding, uncertainty about how long dosing benefits last, the level of support required, safety risks, and uneven health-system capacity. These factors matter for professionals deciding how cautiously to translate trial results into routine practice and service planning.
In mice, administration of the tuberculosis vaccine BCG was linked to a reduced tau burden, apparently by enhancing microglial clearance of tau tangles. The result connects an established vaccine to dementia-related pathology and supports interest in human trials to test whether it can lower dementia risk. It matters as a possible immunomodulatory approach, but the mouse findings still require clinical validation.
Acumen’s Phase 2 trial of sabirnetug in Alzheimer’s disease missed its primary cognitive endpoint despite evidence of amyloid lowering. The company is halting further development of the drug and abandoning planned open-label extension work. The outcome matters because it shows that reducing amyloid does not reliably produce cognitive benefit, a central risk for Alzheimer’s programs.
Neflamapimod failed to meet the primary endpoint in a trial for dementia with Lewy bodies. Biomarker and subgroup signals nevertheless suggested possible impact on the IL-1β pathway, which may justify a phase 3 trial. The mixed result leaves the drug’s DLB path uncertain while providing a hypothesis-generating signal for further study.
A national survey found that most US adults are unaware that medications for alcohol use disorder exist. The study also links safety concerns and racial disparities to hesitation about treatment. For clinicians and public health professionals, the findings suggest that low awareness and underlying concerns may be limiting uptake of evidence-based treatment options.
Research on GLP-1 medications suggests they may dampen persistent food cravings—often called "food noise"—by altering reward and satiety signaling in the brain, which in turn reduces food-seeking behavior and binge-like eating. This matters because it frames the drugs' effects as more than delayed gastric emptying, pointing to central appetite and motivation pathways. However, the evidence on long-term neurological and behavioral outcomes remains unsettled, leaving open questions about durability and clinical implications.
An update on the dementia pipeline highlights phase 2 and 3 activity across Alzheimer disease and Lewy body dementia. A UK adaptive platform trial is evaluating repurposed drugs, while several new phase 2/3 candidates continue to advance. Separately, sleep disruption is being framed as a potentially treatable risk factor. For clinicians and drug developers, the combined message is that therapeutic and modifiable-risk strategies are progressing in parallel.
The weekly brief
One email a week with the stories that moved this field, plus what to watch next.
Fields marked * are required.